Revenio Group (REG1V) Q1 2025 earnings summary

Executive summary

• Net sales reached EUR 26.1 million in Q1 2025, up 10.5% year-over-year, with currency-adjusted growth at 12%.

• EBIT rose 28.6% to EUR 6.6 million, representing 25.4% of net sales, a record level.

• Growth was organic and broad-based, with strong performance in imaging and tonometer product lines across all regions, especially APAC (notably China and India), Europe, and Canada.

• New product launches and regulatory approvals, including FDA and CE for the iCare MAIA microperimeter, supported momentum; commercial deliveries began in April 2025.

• Healthy US sales pipeline and robust product and solution offering contributed to results.

Financial highlights

• Net sales: EUR 26.1 million (+10.5% year-over-year); currency-adjusted sales up 12%.

• EBIT: EUR 6.6 million (+28.6% year-over-year), margin 25.4%; EBITDA: EUR 7.7 million (+24.3%), margin 29.6%.

• EPS improved to EUR 0.157 from EUR 0.137; cash flow from operations was EUR 4.7 million.

• Gross margin improved to 72.6% from 70.3%, partly due to IFRS changes.

• Equity ratio increased to 80.2% from 74.5%; interest-bearing debt reduced to EUR 11.3 million.

Outlook and guidance

• Exchange rate-adjusted net sales for 2025 expected to grow 6–15% year-over-year, aiming for double-digit growth.

• Profitability, excluding non-recurring items, is expected to remain at a good level.

• Uncertainty in the market justifies a wider guidance range.